Shionogi & Co earnings date
Shionogi & Co (SGIOF) Q1 2025 Earnings Report
SGIOF Q1 2025 EPS Results
- Actual EPS
- $0.29
- Consensus EPS
- $0.26
- Beat/Miss
- Beat by +$0.03
- One Year Ago EPS
- $0.23
SGIOF Q1 2025 Revenue Results
- Actual Revenue
- $629.31M
- Expected Revenue
- $660.59M
- Beat/Miss
- Missed by -$31.27M
- YoY Revenue Growth
- +2.25%
Earnings Announcement Details
- Quarter
- Q1 2025
- Date
- 07/28/2025
- Time
- Before Open
- Conference Call
- Monday, July 28, 2025
Shionogi & Co's next earnings date is estimated for February 5, 2027, based on past reporting schedules.
Q1 2025 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q1 2025 Earnings Slide Deck
Q1 2025 Earnings Call Summary
The earnings call highlighted strong financial performance and growth in the HIV business, along with successful M&A activities and advancements in drug development. These positives were tempered by declines in domestic and overseas sales, particularly in China, and concerns regarding R&D cost management. Despite these challenges, the overall outlook remains optimistic due to strategic growth initiatives.
During the first quarter financial results briefing for fiscal year 2025, SHIONOGI reported significant growth in both financial and non-financial metrics. The company achieved a year-over-year increase in revenue to JPY99.8 billion, up by JPY2.2 billion, with operating profit reaching JPY35.1 billion, an increase of JPY7 billion. Profit before tax rose to JPY46.3 billion, up by JPY9.8 billion, and profit attributable to owners of the parent increased by JPY8.7 billion to JPY39.4 billion. EBITDA also saw a rise to JPY40.6 billion, marking a JPY7 billion increase. Significant contributors to this growth included the strong performance of the HIV business, with revenue from this segment driven by ViiV's HIV franchise and royalty income from Roche's Xofluza, which benefited from a flu epidemic in China and the U.S. Non-financial milestones included the completion of a tender offer for Torii Pharmaceutical and progress towards an M&A with the JT Group's pharmaceutical business. The company's strategic focus on pipeline developments, including the filing of Ensitrelvir in Europe and the U.S., is expected to support medium- to long-term growth.
- Strong Financial PerformanceRevenue for Q1 FY2025 increased to JPY99.8 billion, a rise of JPY2.2 billion compared to the same period last year. Operating profit increased by JPY7 billion to JPY35.1 billion, and profit before tax rose by JPY9.8 billion to JPY46.3 billion. Profit attributable to owners of the parent was JPY39.4 billion, an increase of JPY8.7 billion.
- HIV Business GrowthThe HIV business showed strong growth, with ViiV's HIV franchise contributing to higher royalty income. Long-acting formulations like Cabenuva and Dovato are driving this growth.
- Advancements in Drug DevelopmentSignificant progress in the development pipelines, including the filing of Ensitrelvir in Europe and the US. The development of S-365598, a third-generation integrase inhibitor, is ongoing with promising antiviral activity.
- Successful M&A ActivityCompletion of the tender offer for Torii Pharmaceutical and progress towards merging with the JT Group pharmaceutical business.
SGIOF Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 05, 2027 | 2026 (Q3) | 0.41- | 0.55 | ― | ― |
| Oct 29, 2026 | 2026 (Q2) | 0.280.16 | 0.33 | -50.59% (-0.17) | |
| Aug 03, 2026 | 2026 (Q1) | 0.290.72 | 0.29 | 148.18% (+0.43) | |
| May 12, 2026 | 2025 (Q4) | 0.300.35 | 0.27 | 28.10% (+0.08) | |
| May 10, 2026 | 2026 (Q4) | ―0.35 | 0.35 | 0.00% (+0.00) | |
| Jan 30, 2026 | 2025 (Q3) | 0.380.55 | 0.38 | 47.35% (+0.18) | |
| Oct 27, 2025 | 2025 (Q2) | 0.300.33 | 0.39 | -15.86% (-0.06) | |
| Jul 28, 2025 | 2025 (Q1) | 0.260.29 | 0.23 | 28.42% (+0.06) | |
| May 12, 2025 | 2024 (Q4) | 0.300.27 | 0.26 | 5.35% (+0.01) | |
| Jan 31, 2025 | 2024 (Q3) | 0.290.38 | 0.27 | 40.43% (+0.11) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

